News Brief

Medidata, BioGend Therapeutics Partner on Clinical Trial Imaging

Medidata announced recently that BioGend Therapeutics has integrated Medidata Rave imaging with BioGend’s imaging workflow for clinical trials. BioGend Therapeutics is a leading Taiwanese medical device company of holistic medical care to restore bone and joint functions.

BioGend will leverage the seamless integration with electronic data capture (EDC) provided by Rave Imaging to support efficient study trials across all medical imaging activities. Rave imaging is an end-to-end, cloud-based platform for image management in clinical trials. This includes image capture, advanced edit checks, workflow, form design, EDC connection and intelligent archiving. Medidata said it processes more than 500 million images annually from nearly 1000 studies.

By bringing the two data collection environments of EDC and Rave Imaging together, BioGend will benefit from the power of an integrated data platform and save time, resources and cost. This integration leads to streamlined processes, accelerated timelines and greater visibility.

Gwen Chang, Director of Clinical Development Department, BioGend Therapeutics, said, “Rave Imaging has provided us with a structured approach to image submission which dramatically reduces the query rate and ensures the most accurate data is distributed to the right users at the right time. The system automates the distribution and review process after upload, per our own protocol design.”

Edwin Ng, Senior Vice President, General Manager, APAC, at Medidata Solutions said, “As more than half of medical device trials involve imaging support, we believe Medidata’s solutions will ensure that we can support BioGend efficiently without them having to integrate imaging data from external sources.” Edwin added, “We are pleased to be supporting BioGend Therapeutic’s exceptional growth in Taiwan. This partnership is a testament for Medidata’s portfolio of products and our continued commitment to helping our partners streamline and enhance the clinical research process.”

For more information, contact Paul Oestreicher, external communications director at